Severe Onycholysis and Eyelash Trichomegaly Following Use of New Selective Pan-FGFR Inhibitors

JAMA Dermatol. 2017 Jul 1;153(7):723-725. doi: 10.1001/jamadermatol.2017.0500.

Authors

Sarah Bétrian¹, Carlos Gomez-Roca¹, Emmanuelle Vigarios², Jean Pierre Delord¹, Vincent Sibaud³

Affiliations

¹ Departments of Oncology and Clinical Research, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, France.
² Department of Oral Medicine, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, France.
³ Departments of Oncodermatology and Clinical Research, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, France.

PMID: 28538953
DOI: 10.1001/jamadermatol.2017.0500

No abstract available

Publication types

Case Reports

MeSH terms

Eyelashes / drug effects*
Eyelid Diseases / chemically induced*
Eyelid Diseases / diagnosis
Fibroblast Growth Factors / antagonists & inhibitors*
Glioblastoma / drug therapy
Humans
Male
Middle Aged
Onycholysis / chemically induced*
Onycholysis / diagnosis
Pyrazoles / adverse effects*
Pyrazoles / therapeutic use
Quinoxalines / adverse effects*
Quinoxalines / therapeutic use
Severity of Illness Index
Urinary Bladder Neoplasms / drug therapy

Substances

Pyrazoles
Quinoxalines
Fibroblast Growth Factors
erdafitinib